INSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Inspire Medical Systems Inc (INSP) is not a good buy for a beginner investor with a long-term strategy at this time. The stock faces significant uncertainties, including reduced guidance, legal investigations, and coding challenges that may impact future growth. Despite strong financial performance in Q4 2025, the lack of clear positive catalysts and negative sentiment from analysts and news make this stock a risky investment.
The MACD is positive but contracting, suggesting weakening momentum. RSI is neutral at 44.322, indicating no clear overbought or oversold conditions. Moving averages are converging, and the stock is trading below key pivot levels, with support at $57.513 and resistance at $68.538. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Strong Q4 2025 financial performance, including a 12.25% YoY revenue increase and a 301.72% YoY EPS increase.
Reduced FY2026 guidance, legal investigations, securities class action lawsuit, and coding-related challenges that may hinder growth. Analysts have significantly lowered price targets, and sentiment is largely neutral to negative.
In Q4 2025, Inspire Medical Systems reported strong financials with revenue up 12.25% YoY, net income up 286.36% YoY, and EPS up 301.72% YoY. Gross margin also improved to 86.59%. However, these results are overshadowed by reduced guidance and uncertainties.
Analyst sentiment is largely negative. Multiple firms have downgraded the stock or reduced price targets significantly, citing uncertainties related to coding changes, reduced guidance, and legal challenges. Current price targets range from $60 to $85, with most analysts maintaining neutral or cautious ratings.
